MedTrace Logo

Vaccine Therapy in Treating Patients With Kidney Cancer

NCT00096629 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2018-04-25

No results posted yet for this study

Summary

RATIONALE: Vaccines made from DNA may make the body build an immune response to kill tumor cells.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients with kidney cancer.

Conditions

Interventions

BIOLOGICAL

human prostate-specific membrane antigen plasmid DNA vaccine

BIOLOGICAL

mouse prostate-specific membrane antigen plasmid DNA vaccine

Sponsors & Collaborators

Principal Investigators

  • Susan Slovin, MD, PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-11-30
Primary Completion
2018-04-30
Completion
2018-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00096629 on ClinicalTrials.gov